SEC Form 4 · accession 0001193125-26-395893
Definium Therapeutics, Inc. · DFTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andreas Krebs
Director
Period of report
Sep 18, 2026
Accepted (ET)
Sep 18, 2026 · 9:55 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001813814
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | Sep 18, 2026 | M | 1,629 | $35.52 | A | 21,402 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $35.52 | Sep 18, 2026 | M | 1,629 | D | Sep 29, 2021 | Sep 29, 2026 | Common Shares | 1,629 | 0 | D |